Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares made a solid gain on Tuesday after the company gave an update on its midstage study. Specifically, the firm announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection.
With this trial underway, Arrowhead stands to continue its incredible breakout. Excluding Tuesday’s move, Arrowhead has outperformed the broad markets, with its stock up over 270% in the past 52 weeks. In just 2018 alone, the stock is up nearly 90%.
What stands out here is that ARO-HBV is the second clinical candidate developed using Arrowhead’s proprietary Targeted RNAi Molecule technology.
This study is evaluating the safety, tolerability and pharmacokinetic effects of single-ascending doses of ARO-HBV in healthy adult volunteers and evaluating the safety, tolerability and pharmacodynamic effects of multiple-ascending doses of ARO-HBV in patients with chronic HBV.
Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, commented:
We are proud of how quickly ARO-HBV moved through preclinical studies and are excited to be starting first-in-human clinical studies. The AROHBV1001 Phase 1/2 clinical study has an innovative design that is intended to assess, in parallel, safety and tolerability in healthy volunteers and multiple-dose anti-viral activity in HBV patients. Our experience with two prior compounds, ARC-520 and ARC-521, provides us with confidence that ARO-HBV, which is designed to target all viral transcripts, including those produced by both cccDNA and HBV DNA integrated into host DNA, has the potential to be a backbone therapy in combinations aimed at achieving a functional cure of chronic HBV infection.
Shares of Arrowhead traded up 14% at $7.95 on Tuesday, with a consensus analyst price target of $5.50 and a 52-week range of $1.42 to $8.09.
24/7 Wall St.Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
